Literature DB >> 2646125

Acute myelogenous leukaemia in children.

S O Lie1.   

Abstract

Acute myelogenous leukaemia in childhood is considerably more resistant to chemotherapy than the acute lymphocytic leukaemias. Recently, more aggressive therapy has improved the outlook for children with this difficult form of leukaemia. Long-term disease-free survival of children achieving remission has been reported to be more than 40% in some studies. This paper reviews both the present concept of leukaemogenesis as well as some of the more recent therapeutic studies on childhood AML.

Entities:  

Mesh:

Year:  1989        PMID: 2646125     DOI: 10.1007/bf00595892

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  101 in total

1.  Primary human myeloid leukemia cells: comparative responsiveness to proliferative stimulation by GM-CSF or G-CSF and membrane expression of CSF receptors.

Authors:  C G Begley; D Metcalf; N A Nicola
Journal:  Leukemia       Date:  1987-01       Impact factor: 11.528

2.  Long-term relapse-free survival in childhood acute nonlymphocytic leukemia.

Authors:  S O Lie; S H Slørdahl
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

Review 3.  Preleukaemia.

Authors:  H P Koeffler
Journal:  Clin Haematol       Date:  1986-08

Review 4.  The case for high-dose chemotherapy: is it chemotherapy's last gamble?

Authors:  G P Canellos
Journal:  Eur J Cancer Clin Oncol       Date:  1987-04

5.  Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study.

Authors:  H Preisler; R B Davis; J Kirshner; E Dupre; F Richards; H C Hoagland; S Kopel; R N Levy; R Carey; P Schulman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

Review 6.  Acute myelogenous leukemia: recent advances in therapy.

Authors:  R Champlin; R P Gale
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

7.  Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.

Authors:  F Brito-Babapulle; D Catovsky; G Slocombe; A C Newland; R E Marcus; J M Goldman; D A Galton
Journal:  Cancer Treat Rep       Date:  1987-02

8.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

9.  High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study.

Authors:  S N Wolff; J Marion; R S Stein; J M Flexner; H M Lazarus; T R Spitzer; G L Phillips; R H Herzig; G P Herzig
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

10.  Acute nonlymphocytic leukemia: heterogeneity of stem cell origin.

Authors:  P J Fialkow; J W Singer; J W Adamson; K Vaidya; L W Dow; J Ochs; J W Moohr
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

View more
  2 in total

1.  Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany.

Authors:  J Ritter; U Creutzig; A Reiter; H Riehm; G Schellong
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.

Authors:  J Vormoor; J Ritter; U Creutzig; J Boos; P Heyen; W D Ludwig; J Harbott; H Löffler; G Schellong
Journal:  Br J Cancer Suppl       Date:  1992-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.